Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Totus Medicines","sponsor":"DCVC Bio","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Totus Medicines Emerges from Stealth with Revolutionary Drug Program Targeting PI3K-Alpha Oncogene","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Totus Medicines CEO to Present at Next-Generation Undruggable Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Totus Medicines Announces Poster Presentation for TOS-358, the First Highly Selective Covalent Molecule Targeting PI3K\u03b1, at the 34th EORTC-NCI-AACR Symposium in Barcelona","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Totus Medicines Announces First Patient Dosed in Phase 1 Trial of TOS-358 for the Treatment Of Select Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"DCVC Bio","pharmaFlowCategory":"D","amount":"$66.0 million","upfrontCash":"Undisclosed","newsHeadline":"Totus Medicines Closes $66M Series B to Fund Early-Stage PI3Ka Inhibitor, Names New CEO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Totus Medicines Announces Strategic Multi-Target Research Collaboration with Lilly","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Technology","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by Totus Medicines

    Menu

    Totus Medicines

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Totus Medicines

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Totus Medicines Announces Strategic Multi-Target Research Collaboration with Lilly

              Details:

              Under the terms of the agreement, Totus Medicines will use its proprietary OmniDEL platform to discover small molecule drug candidates against Lilly's undisclosed targets.

              Lead Product(s): Undisclosed

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Eli Lilly

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 16, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Totus Medicines

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Totus Medicines Closes $66M Series B to Fund Early-Stage PI3Ka Inhibitor, Names New CEO

              Details:

              The net proceeds will be used for the advancement of company's pipeline of clinical candidates led by TOS-358, a covalent inhibitor of PI3Ka for the treatment of adults with select solid tumors.

              Lead Product(s): TOS-358

              Therapeutic Area: Oncology Product Name: TOS-358

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: DCVC Bio

              Deal Size: $66.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing December 15, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Totus Medicines

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Totus Medicines Announces First Patient Dosed in Phase 1 Trial of TOS-358 for the Treatment Of Select Solid Tumors

              Details:

              TOS-358 is the company's first-in-class covalent, highly specific, potent PI3Kα inhibitor for the treatment of numerous cancers with known PIK3CA mutations.

              Lead Product(s): TOS-358

              Therapeutic Area: Oncology Product Name: TOS-358

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 13, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Totus Medicines

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Totus Medicines Announces Poster Presentation for TOS-358, the First Highly Selective Covalent Molecule Targeting PI3Kα, at the 34th EORTC-NCI-AACR Symposium in Barcelona

              Details:

              TOS-358 is a highly selective covalent inhibitor of PI3Kα. TOS-358 demonstrates clear superiority compared to non-covalent molecules by achieving deep and durable inhibition of PI3K-AKT signaling.

              Lead Product(s): TOS-358

              Therapeutic Area: Oncology Product Name: TOS-358

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 27, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Totus Medicines

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Totus Medicines CEO to Present at Next-Generation Undruggable Conference

              Details:

              TOS-358, the first highly selective covalent molecule targeting PI3Kα, which is the most mutated oncogene in cancer, induces stasis and regression across PI3Kα mutant models.

              Lead Product(s): TOS-358

              Therapeutic Area: Oncology Product Name: TOS-358

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 11, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Totus Medicines

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Totus Medicines Emerges from Stealth with Revolutionary Drug Program Targeting PI3K-Alpha Oncogene

              Details:

              The Series A financing will be used to expand and scale Totus Medicines' proprietary drug discovery platform and advance the company's TOS-358 drug program targets the PI3K? mutation into the clinic.

              Lead Product(s): TOS-358

              Therapeutic Area: Oncology Product Name: TOS-358

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: DCVC Bio

              Deal Size: $40.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing December 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY